Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808418 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 5
- Study locations
NCT00808418: Completed Phase 1 study of Prostate Cancer, sponsored by Synta Pharmaceuticals.
NCT00808418 is a Phase 1 study of Prostate Cancer that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 34 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00808418, a Phase 1 study of Prostate Cancer, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 5
- Study locations
Study Summary
This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomol and docetaxel.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Elesclomol Sodium
Study Locations (5)
California
- Pacific Coast Hematology/Oncology Medical Group - Fountain Valley
Maryland
- Mayo Clinic - Rochester
North Dakota
- Mid Dakota Clinic - Bismarck
Texas
- University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development - San Antonio
Wisconsin
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
What the finished NCT00808418 record still lists
NCT00808418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT00808418 lists 5 locations in 5 states (California, Maryland, North Dakota).
Frequently Asked Questions
What is clinical trial NCT00808418 about?
NCT00808418 is a clinical study titled "A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer". This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomo...
What is the current status of trial NCT00808418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2008-11. Estimated completion is 2010-05.
What conditions does trial NCT00808418 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00808418?
The interventions under investigation include: Docetaxel (DRUG), Elesclomol Sodium (DRUG).
Who is sponsoring clinical trial NCT00808418?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808418 being conducted?
This trial has 5 study locations across California, Maryland, North Dakota, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00808418's enrollment target sits among peer trials
34 557th of 735 higher than 177 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia